Description
Regorafenib Tablets 40mg (commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had 2 US approvals for advanced cancers.
| Strength | 40 mg |
| Pack Size | 28 Tablets per bottle |
| Brand | Regonat |
| Packaging Type | Box |
| Composition | Regorafenib (40mg) |
| Form | Tablet |
| Shelf Life | 24 Months |
| Usages | Not specified |
| Country of Origin | Not specified |
